Literature DB >> 23436150

Cell signaling abnormalities may drive neurodegeneration in familial Alzheimer disease.

Nikolaos K Robakis1.   

Abstract

Presenilins (PSs) are catalytic components of the γ-secretase complex that produces Aβ peptides. Substrates of γ-secretase are membrane-bound protein fragments deriving from the cleavage of extracellular sequence of cell surface proteins. APP-derived γ-secretase substrates are cleaved at gamma (γ) sites to produce Aβ while cleavage at the epsilon (ε) site produces AICD proposed to function in transcription. In addition to APP, γ-secretase promotes the ε-cleavage of a large number of cell surface proteins producing cytosolic peptides shown to function in cell signaling. A common hypothesis suggests that Alzheimer's disease (AD) is caused by Aβ peptides or their products. Treatment of patients with inhibitors of Aβ production however, showed no therapeutic benefits while inducing cytotoxicity. Similarly, treatments with anti-Aβ antibodies yielded disappointing results. Importantly, recent evidence shows that PS familial AD (FAD) mutations cause a loss of γ-secretase cleavage activity at ε site of substrates thus inhibiting production of biologically important cell signaling peptides while promoting accumulation of membrane-bound cytotoxic substrates. These data support a hypothesis that FAD mutations may increase neurotoxicity by inhibiting the γ-secretase-catalyzed ε cleavage of substrates thus interfering with cell signaling while also promoting accumulation of cytotoxic peptides. Similar mechanisms may explain γ-secretase inhibitor-associated toxicities observed in clinical trials. Here we discuss evidence that FAD neurodegeneration may be caused by loss of γ-secretase cleavage function at ε sites of substrates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23436150      PMCID: PMC3718870          DOI: 10.1007/s11064-013-1003-6

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  49 in total

1.  Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease.

Authors:  M A Pappolla; R A Omar; K S Kim; N K Robakis
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

2.  Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42.

Authors:  Marco Duering; Marcus O W Grimm; Heike S Grimm; Johannes Schröder; Tobias Hartmann
Journal:  Neurobiol Aging       Date:  2005-06       Impact factor: 4.673

3.  FAD mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta.

Authors:  Junichi Shioi; Anastasios Georgakopoulos; Pankaj Mehta; Zen Kouchi; Claudia M Litterst; Lia Baki; Nikolaos K Robakis
Journal:  J Neurochem       Date:  2007-01-24       Impact factor: 5.372

4.  Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations.

Authors:  Huiping Tu; Omar Nelson; Arseny Bezprozvanny; Zhengnan Wang; Sheu-Fen Lee; Yi-Heng Hao; Lutgarde Serneels; Bart De Strooper; Gang Yu; Ilya Bezprozvanny
Journal:  Cell       Date:  2006-09-08       Impact factor: 41.582

5.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

Authors:  D Scheuner; C Eckman; M Jensen; X Song; M Citron; N Suzuki; T D Bird; J Hardy; M Hutton; W Kukull; E Larson; E Levy-Lahad; M Viitanen; E Peskind; P Poorkaj; G Schellenberg; R Tanzi; W Wasco; L Lannfelt; D Selkoe; S Younkin
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

6.  Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status.

Authors:  Constantin Bouras; Enikö Kövari; François R Herrmann; Claire-Bénédicte Rivara; Thomasina L Bailey; Armin von Gunten; Patrick R Hof; Panteleimon Giannakopoulos
Journal:  J Neuropathol Exp Neurol       Date:  2006-03       Impact factor: 3.685

7.  Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo.

Authors:  D R Borchelt; G Thinakaran; C B Eckman; M K Lee; F Davenport; T Ratovitsky; C M Prada; G Kim; S Seekins; D Yager; H H Slunt; R Wang; M Seeger; A I Levey; S E Gandy; N G Copeland; N A Jenkins; D L Price; S G Younkin; S S Sisodia
Journal:  Neuron       Date:  1996-11       Impact factor: 17.173

8.  Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease.

Authors:  D L Miller; I A Papayannopoulos; J Styles; S A Bobin; Y Y Lin; K Biemann; K Iqbal
Journal:  Arch Biochem Biophys       Date:  1993-02-15       Impact factor: 4.013

9.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus.

Authors:  E Levy-Lahad; W Wasco; P Poorkaj; D M Romano; J Oshima; W H Pettingell; C E Yu; P D Jondro; S D Schmidt; K Wang
Journal:  Science       Date:  1995-08-18       Impact factor: 47.728

10.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.

Authors:  R Sherrington; E I Rogaev; Y Liang; E A Rogaeva; G Levesque; M Ikeda; H Chi; C Lin; G Li; K Holman; T Tsuda; L Mar; J F Foncin; A C Bruni; M P Montesi; S Sorbi; I Rainero; L Pinessi; L Nee; I Chumakov; D Pollen; A Brookes; P Sanseau; R J Polinsky; W Wasco; H A Da Silva; J L Haines; M A Perkicak-Vance; R E Tanzi; A D Roses; P E Fraser; J M Rommens; P H St George-Hyslop
Journal:  Nature       Date:  1995-06-29       Impact factor: 49.962

View more
  5 in total

1.  Is Alzheimer's disease a homogeneous disease entity?

Authors:  Amos D Korczyn
Journal:  J Neural Transm (Vienna)       Date:  2013-08-11       Impact factor: 3.575

2.  Protective effect of tetrahydroxy stilbene glucoside on learning and memory by regulating synaptic plasticity.

Authors:  Hong-Bo Luo; Yun Li; Zun-Jing Liu; Li Cao; Zhi-Qiang Zhang; Yong Wang; Xiao-Yan Zhang; Zhao Liu; Xiang-Qun Shi
Journal:  Neural Regen Res       Date:  2016-09       Impact factor: 5.135

3.  Early pathogenic event of Alzheimer's disease documented in iPSCs from patients with PSEN1 mutations.

Authors:  Juan Yang; Hanzhi Zhao; Yu Ma; Guilai Shi; Jian Song; Yu Tang; Song Li; Ting Li; Nan Liu; Fan Tang; Junjie Gu; Lingling Zhang; Zhuohua Zhang; Xiaohui Zhang; Ying Jin; Weidong Le
Journal:  Oncotarget       Date:  2017-01-31

Review 4.  Induced pluripotent stem cells in Alzheimer's disease: applications for disease modeling and cell-replacement therapy.

Authors:  Juan Yang; Song Li; Xi-Biao He; Cheng Cheng; Weidong Le
Journal:  Mol Neurodegener       Date:  2016-05-17       Impact factor: 14.195

5.  Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease.

Authors:  Sepideh Parsi; Pascal Y Smith; Claudia Goupil; Véronique Dorval; Sébastien S Hébert
Journal:  Mol Ther Nucleic Acids       Date:  2015-10-06       Impact factor: 10.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.